IQVIA Selects Veeva Applications for Clinical Development
News related to:IQVIA · 3 min read
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Oct. 13, 2026 /CourierPR/ -- IQVIA, a leading global provider of clinical research services, has expanded its partnership with Veeva Systems by selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for use across IQVIA's clinical development studies. This move builds on the previously announced EDC partnership and aims to enhance the efficiency and speed of clinical trials, as well as strengthen site-centricity.
According to Richard Staub, president of Research and Development Solutions at IQVIA, the partnership brings together the strengths of both companies to provide clinical teams with a more connected way to work.
The integration of Veeva's clinical solutions into IQVIA's workflow is expected to streamline the clinical development process, making it more efficient and effective. All Veeva clinical solutions are now available through IQVIA for sponsors who wish to enable a full Veeva technology stack.
IQVIA's portfolio of solutions, powered by IQVIA Connected Intelligence, delivers actionable insights and services built on high-quality health data, healthcare-grade AI, advanced analytics, and extensive domain expertise. The company is dedicated to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance, and patient safety.
Veeva Systems, a global provider of the industry cloud for life sciences, serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
IQVIA and Veeva will host the Veeva R&D and Quality Summit on October 20-21 in Boston, where attendees can learn more about the expanded partnership and the latest advancements in clinical research. The event will provide a platform for stakeholders to explore how the integration of Veeva's solutions can enhance the clinical development process and improve patient outcomes.
IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, healthcare-grade AI, advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance, and patient safety, and delivering AI to the high standards of trust, scalability, and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Veeva Systems (NYSE: VEEV) delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.